Oct 30 (Reuters) - Amylin Pharmaceuticals Inc:
* Says Byetta approved for expanded use as first-line treatment for type 2
diabetes
* Amylin Pharmaceuticals Inc and Eli Lilly and Co says byetta now
approved for use as a stand-alone medication to improve glycemic control in
adults with type 2 diabetes
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Amylin Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says Byetta approved for expanded use as first-line treatment for type 2
diabetes
* Amylin Pharmaceuticals Inc and Eli Lilly and Co says byetta now
approved for use as a stand-alone medication to improve glycemic control in
adults with type 2 diabetes
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Amylin Pharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
© 2009 AFX News
